

Commissioner for Patents

AMENDMENTS TO THE CLAIMS

This listing of the claims replaces all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1. (Withdrawn)
2. (Withdrawn)
3. (Withdrawn)
4. (Withdrawn)
5. (Allowed in Parent Application Serial No. 09/494,500)
6. (Withdrawn)
7. (Withdrawn)
8. (Currently Amended) A method for the prevention, treatment and/or reduction of Kaposi's sarcoma (KS) and/or HIV ~~expression~~—in AIDS patients, ~~which comprises~~said method comprising administering to said patients a therapeutically effective amount of a compound of claim 1 pharmaceutical composition having inhibitory activity on Kaposi's sarcoma (KS) and/or HIV which comprises a therapeutically effective amount of at least one compound having anti-KS and/or anti-HIV activity and comprising a biologically active compound comprising a protein and/or fragment thereof isolated from a biologically active fraction of APLTM-HCG.

Commissioner for Patents

9. (Withdrawn)
10. (Withdrawn)
11. (Withdrawn)
12. (Withdrawn)
13. (Allowed in Parent Application Serial No.
09/494,500)
14. (Allowed in Parent Application Serial No.
09/494,500)
15. (Allowed in Parent Application Serial No.
09/494,500).
16. (New) The method as claimed in claim 8 wherein
said protein and/or active fragment thereof is a
polypropylene adsorbing compound.
17. (New) The method as claimed in claim 16 wherein
said protein and/or fragment thereof lacks HCG
steroidogenic ability and lacks ability to bind to the
lutropin-choriogonadotropin receptor.
18. (New) The method as claimed in claim 8 wherein
said protein and/or fragment thereof comprises a
sequence selected from the group consisting of SEQ ID
NOS: 1 and 4 in association with a pharmaceutically
acceptable carrier.

Commissioner for Patents

19. (New) The method as claimed in claim 18 wherein said at least one compound is also a polypropylene adsorbing compound which lacks the HCG steroidogenic ability and lacks the ability to bind to the lutropin-choriogonadotropin receptor.

20. (New) The method as claimed in claim 8 wherein said protein and/or fragment thereof comprises SEQ ID NO: 1 in association with a pharmaceutically acceptable carrier.

21. (New) The method as claimed in claim 20 wherein said at least one compound is also a polypropylene adsorbing compound which lacks the HCG steroidogenic ability and lacks the ability to bind to the lutropin-choriogonadotropin receptor.